Injecting the brain molecule into mouse models of multiple sclerosis increased the number of oligodendrocytes. The findings suggest fractalkine may help to slow the progression, or potentially halt multiple sclerosis.
Teenagers who suffer from inadequate or disrupted sleep may be at higher risk of developing multiple sclerosis later in life.
Researchers found significant functional connectivity between multiple sclerosis lesion location and the patient's a priori depression circuit. Findings provide a novel localization of multiple sclerosis-related depression.
Study reveals differences in the composition and functionality of intestinal bacteria of multiple sclerosis patients depending on whether their illness is active or whether they are in treatment.
A Tool to Investigate Rare, Previously Inaccessible Cells That Play a Key Role in Multiple Sclerosis
Researchers have developed a new method to pinpoint a subset of astrocytes that appear to play a role in the development and progression of multiple sclerosis.
In PV cells, axons with myelin contain more mitochondria. When myelin is decreased in PV cells, mitochondria also decrease. However, mitochondria increase when myelin is lost in excitatory cells.
Researchers found significantly higher levels of Lcn-2 levels in the stools of patients with multiple sclerosis. This marker correlated with reduced bacterial diversity and increases in other markers of intestinal inflammation. Bacteria that ease inflammatory bowel disease were also reduced in MS patients with high fecal levels of Lcn-2 levels.
Fatigue is a common symptom associated with multiple sclerosis, affecting up to 99% of patients. Researchers report light box therapy helped measurably improve symptoms of fatigue in those with MS after 14 days.
Study identified three new genes that appear to be involved in the pathologies associated with multiple sclerosis.
CAR-T, a therapy generally used in the treatment of cancer, has been shown to eliminate unhealthy cells that trigger autoimmunity in mouse models of multiple-sclerosis.
Riluzole, an FDA-approved drug to treat ALS, can, in part, correct the molecular cause of some leukodystrophies.
Multiple sclerosis patients treated with dimethyl fumarate (Tecfidera) showed a reduced proportion of pro-inflammatory types of gut bacteria and an increased growth of "good" bacteria after three months of treatment.
